Lung cancer is the leading cause of cancer deaths worldwide in both women and men. Non-small-cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases, with adenocarcinoma (LUAD) being the major subtype. General failure of response to conventional therapies, a limited number of treatment options, and diagnosis at a late stage are all hallmarks of this devastating disease. Hence, a better understanding of lung cancer is greatly needed. Our research laboratory focuses on the immunologic and metabolic perturbations of lung cancer, with an emphasis on tumor-associated neutrophils (TAN), innate immune cells that may be critical for tumor development and therapy resistance.